Posts Tagged ‘cardio’


In STEM CELLS IN THE NEWS on April 12, 2012 at 1:31 pm

My buddy David S. is raising funds for stem cell treatment for his heart.  He is a gentleman, a poet, a musician and he always seems to get right to the meat of the subject.  David asks:

What was the method used to develop [adult stem cell] therapies all over the world in other countries? Clinical trials?


Excellent question!

Short answer: American medical professionals are so Ameri-centric, they throw away or ignore anything (studies, trials, etc) conducted outside the USA.

I remember a few years ago, an acquaintance of mine who was pre-med sneered at my mention of any trials conducted outside the US and then sneered at the very thought of adult stem cells doing anything.  Well, I guess I’m laughing last but I brought up the point then that his arrogance was somewhat confusing to me since the USA health system is ranked 37th in the world by the World Health Organization.  What the hell was he so proud of??


in 2005 the first stem cell treatment facility was created in Thailand where the environment was favorable (the king’s cardio thoracic surgeon was a fan of stem cells for heart disease) and theIr methods were based on half a decade of human research preceded by years and years of animal research. I present a short list of the ‘ignored’ studies below.  Read through and you will realize:

a. by the time these studies were published, everyone in the scientifically community new the results for a year or years and

b. by the time the Bangkok facility was created, Prof Doris Taylor was already creating hearts with stem cells from scratch

c. these studies and trials, when conducted outside the US, have been all but ignored and then repeated in the US. The inevitable successful trial results 6-8 years later in the US are always accompanied by an incorrect, ignorant and infuriating news article crying: “first ever in the world!”

d.  in addition to the studies/trials below, there were also hundreds or thousands of other studies showing the safety and efficacy of adult stem cell treatments in animals and humans in other organs/parts of the body.

[While, ‘it worked there, so it will work here’ is not an accepted scientific method, at some point there is an increase in confidence when you realize: adult stem cells are in the body to repair, that’s what they do, they are safe, they fix stuff, now let’s figure out how to maximize there effects.]

For more information: https://repairstemcell.wordpress.com/heart-disease-treatment/



A clinical trial led by Dr. Hans Dohmann plus six colleagues in Brazil took 21 transplant candidates and gave 14 of them bone marrow cells. The results were so spectacular that the American Heart Association accepted the paper and it was presented in 2003. Five of the seven in the control group opted in to make a total of 19 stem cell transplants. The mortality rate for transplant candidates is about 35% per year. At that rate there would be, of those 19, only 2.2 patients still alive without a transplant after five years. There were, in fact, 12 alive as of Dec. 31, 2007; more than five years down the road.

If you did not want or could not get a heart transplant (as is true of 90%+ of dying heart patients in North America) then you had to make a choice between stem cell treatment or standard Western Cardiology methodology.

Western Cardiology methodology kept 12% of patients (waiting for heart transplants) alive for five years.

Adult/repair Stem cell treatments kept 63% of patients (waiting for heart transplants) alive for five years. More than 5 times more heart transplant candidates lived for 5 years with stem cell treatments than the typical heart transplant recipient! Btw, stem cell science has made huge advancements in treating heart disease over the past seven years.


Dr. Andreas Zeiher of the Goethe Institute in Frankfurt began much larger trials. As of 2007, he has overseen more ASC implants into hearts than anyone, both in and out of clinical trials and he was the first to prove that timely implant of RSC in new heart attack victims improves future mortality and morbidity – http://circ.ahajournals.org/cgi/search?journalcode=circulationaha&fulltext=zeiher


Dr. Amit Patel of Pittsburgh completed two of the most successful trials ever. In Uruguay, he proved, on a group of ischemic heart failure patients, that a bypass plus cells was infinitely better than a bypass only. That same year, TheraVitae, in Israel, developed a new, powerful blood-derived stem cell and dared to treat the sickest patients no clinical trial (except Brazil) would consider.

One of the Brazilians, Dr. Perin, came to Texas, used the Brazil results to get the first ASC heart clinical trial approved by the FDA. Over a dozen such approvals were granted in the next 12-18 months.

The first-ever commercial stem cell treatment center in the world starts adult stem cell treatment of hundreds of human patients. Results are amazing and include the regrowing of cardiac muscle tissue in patients, significant increases and sometimes a doubling of ejection fractions (the % volume of blood the heart can pump out per beat), etc! Stem cells are also recognized as “smart,” going to where they were needed most, creating micro-vessel bypasses around existing blockages areas, areas that previously were blocked and in areas where stents were implanted.


Dr Taylor removed all cells from rat hearts except for a thin skeleton of tissue translucent as wax paper. She then injected the scaffold with fresh Cardiac Repair Stem Cells from newborn rats. Four days later, “We could see these little areas that were beginning to beat. By eight days, we could see the whole heart beating.” The experiment, reported in the journal Nature Medicine, marked the first time scientists created a functioning heart in the lab from biological tissue.


HEART DISEASE TRIAL – 2004 to 2006 –

Clinical trial illustrates the safety and efficacy of VesCell Adult Stem Cell treatment. Accepted by the American Heart Assn in 2005-6. This trial was a key element in attaining regulatory approval for the treatment protocol that improved the lives of 300 mostly “no-option” heart patients.


Research paper shows that peripheral blood derived stem cells can differentiate into a variety of other stem cells (angiogenic, myocardial and neural lineages) and do so in sufficient quantities to use as autologous treatment for a variety of diseases.


Clinical study at Chao Phya Hospital Heart Center and Siriraj Hospital H.M. Cardiac Center clinical study shows that transcoronary injection of angiogenic cells precursors improved cardiac/left ventricular ejection fraction (LVEF), exercise capacity and quality of life with high safety profile for 70% of ischemic cardiomyopathy patients with no-option revascularization.


Bangkok Heart Hospital and U of Pittsburgh Medical Center/McGowan Institute for Regenerative Medicine clinical trial shows that expanded autologous blood derived stem cells utilized in intramyocardial transplantation is feasible and safe in severely ill patients with intractable heart failure in all cases of dilated cardiomyopathy (DCM) and in both first-time and “redo” ischemic cardiomyopathy (ICM) patients.


Shows the safety, and feasibility and enhancement of limb salvage from implantation of non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) in 80% of patients with critical limb ischemia (CLI) who were poor candidates for standard revascularization treatment options.


Bioprocessing Journal scientific paper shows the consistent and reliable manufacturing procedure utilized for transforming bone marrow and blood-derived stem cells into angiogenic cell precursors (ACPs) and hematopoietic stem cell (HSC) cellular products for the treatment of severe heart diseases. End product was found to be a) safe and effective; b) prepared from non-mobilized peripheral blood; c) stable, with a relatively long shelf-life; and d) ready-to-use and easily utilized by the physician.

The Future of Stem Cell Research: BCVS Advances in 2010 – AHA Science Network

In STEM CELLS IN THE NEWS on March 9, 2011 at 1:14 pm

Basic Cardiovascular Science Advances for 2010: The Future of Stem Cell Research

By Dr. Mark Sussman

The mission of our council is to improve understanding of mechanisms of basic cardiovascular regulation to support the development of new therapies and insights into clinical cardiovascular disease. Special emphasis is placed on integrating molecular/cellular and physiological approaches to address problems relating to functional genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology and peripheral vascular disease. The council plays a major role in linking basic science to clinical science and is concerned with advancing and applying knowledge derived from basic science to the patient.

Annually AHA asks all of its Councils and science groups what in their estimation have been the most important advances in their respective fields within the past year. We have pulled out of all of those suggestions the ones that came from or are relevant to our community. Several studies this year brought the future of medicine closer to the present with new insight into emerging technologies. These studies evaluate the role of stem cells in cardiac repair and their ability to differentiate into cardiac myocytes and the ability of the heart to replace and regenerate myocytes on its own. The findings from stem cell therapy have been shown to improve quality of life and survival in patients with chronic heart failure and support the development of future cell based therapeutics.

Dr. Mark Sussman is the Chair of the BCVS Council. He is the Distinguished Professor of Biology at the SD


Posted by Melissa AHA Science on Mar 9, 2011 9:13 AM CST

The Cardiomyopathy Association | Dogs with cardiomyopathy in stem cell study

In STEM CELLS IN THE NEWS on July 15, 2010 at 10:09 am

Dogs with cardiomyopathy in stem cell study

Doberman pinschers with dilated cardiomyopathy are to undergo stem cell treatment in America

Doberman pinschers with early stage dilated cardiomyopathy (DCM) are to undergo stem cell treatment to help improve their hearts.

Up to 15 dogs are to be treated at the University of Florida’s Veterinary Medical Centre with $72,000 in support from the Doberman Pinscher Club of America.

The chief of the centre’s cardiology service, Amara Estrada, said “Dobermans have the highest prevalence of dilated cardiomyopathy of any breed of dog and also the most devastating course. So this was the most important and emergent group to focus on.”

It is then hoped the research team can pursue larger-scale clinical trials for Dobermans with DCM.

Research has already suggested that stem-cell transplants can help left ventricular pump function in both animals and humans who have had heart attacks.

All the dogs in the study will be anaesthetised and researchers will inject cells via a catheter into the heart. There will be follow-up checks at one month, six months, 12 months and 18 months.

If the new technique is effective, it may result in less expensive treatment compared to open heart surgery, said Dr Estrada.

Down the road, researchers may expand the studies to include other dog breeds in the hope of achieving beneficial results for all dogs.

The procedure ultimately could be available to veterinary specialists some day, she added.

Cardiomyopathy is common in many breeds of dog.

via The Cardiomyopathy Association | Dogs with cardiomyopathy in stem cell study.

Blocked Arteries Not Always Found on Angiograms | PreDisease.com Blog

In BUSINESS OF STEM CELLS on March 25, 2010 at 5:57 pm

Blocked Arteries Not Always Found on Angiograms

by Jennifer Bunn, RN

Angiograms are the definitive test for people who may have had a heart attack, or who suffer from chest pain. A normal angiogram virtually rules out the possibility of a heart attack. However, a new study finds that this invasive and expensive test yields far fewer positive results than previously thought.

Researchers studied almost 399,000 patients seen in 663 hospitals over a four-year period. What they found was surprising: only 38% of those undergoing angiograms were found to have blocked arteries. Those patients who had had non-invasive tests prior to angiogram with a positive finding (such as an abnormal stress test) were moderately more likely to have blockage of their arteries discovered on angiogram. Researchers noted that risk factors for finding blockage on angiogram were the same risk factors for cardiovascular disease, including:

* Being male

* Being of older age

* Being diabetic

* Having elevated cholesterol levels

Given that angiograms are both expensive and invasive, it would seem that more stringent criteria is needed to determine who requires an angiogram and who does not. It may be that the culture of practicing defensive medicine is responsible for the number of angiograms done on people with normal findings. It is important to keep in mind that angiograms themselves are not without risk, including the risk of bleeding, and should be reserved for those who truly need it.

Source: Obstructive Disease Not Found on Most Angiograms

via Blocked Arteries Not Always Found on Angiograms | PreDisease.com Blog.

FDA Warns about Increased Risk of Muscle Injury with Zocor

In OFF THE BEATEN PATH on March 24, 2010 at 8:14 pm


For Immediate Release: March 19, 2010

Media Inquiries: Elaine Gansz Bobo, 301-796-7567; elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

FDA Warns about Increased Risk of Muscle Injury with Zocor

Highest approved dose of cholesterol-lowering medication could cause harm to muscles

The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. Although muscle injury (called myopathy) is a known side effect with all statins, today’s warning highlights the greater risk of developing muscle injury, including rhabdomyolysis, for patients when they are prescribed and use higher doses of this drug. Rhabdomyolysis is the most serious form of myopathy and can lead to severe kidney damage, kidney failure, and sometimes death.

“Review of simvastatin is part of an ongoing FDA effort to evaluate the risk of statin-associated muscle injury and to provide that information to the public as it becomes available,” said Eric Colman, M.D., Deputy Director of FDA’s Division of Metabolism and Endocrinology Products (DMEP). “It’s important for patients and healthcare professionals to consider all the potential risks and known benefits of any drug before deciding on any one therapy or dose of therapy.”

Simvastatin is sold as a single-ingredient generic medication and as the brand-name Zocor. It also is sold in combination with ezetimibe as Vytorin, and in combination with niacin as Simcor.

FDA’s review of new information on the risk of muscle injury is derived from clinical trials, observational studies, adverse event reports, and prescription use data. The agency also is reviewing data from the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial, which evaluated major cardiovascular events, such as heart attack, revascularization and cardiovascular death, in patients taking 80 mg compared to 20 mg of simvastatin. SEARCH also included data on muscle injury in patients taking simvastatin…

via FDA Warns about Increased Risk of Muscle Injury with Zocor.

Cardiomyopathy Patient Can Do Triathlon After Adult Stem Cells

In VICTORIES & SUCCESS STORIES on March 8, 2010 at 9:00 pm

Don’t miss any important stem cell news! Follow me on twitter! http://twitter.com/stemcellblogger

Eighteen months in the life of Jason Ludwick has been dominated by what he could do. He was in and out of hospital and living with a cocktail of expensive drugs to try to keep your heart failing operation. Then, like hundreds of others went to Thailand for adult stem cell therapy for real help heart disease.

Jason Ludwick aged 34 from West Bloomfield, Michigan, counts himself a lucky man. Born with an atrial septal defect, when I was 15 had a pacemaker, 21, was diagnosed as having cardiomyopathy and 25 had a defibrillator in place and an ejection fraction only 8-10 percent. Heart failure dominated and restricted his life until he received adult stem cell therapy. Now he says that with the training I could do a triathlon.

While his teammates ran and played sports, Jason’s life has been dominated by his illness and his heart does not guarantee which does not run and do not practice any contact sport. I was in and out of hospital and living in a cocktail of expensive drugs. Bled your kidneys, your inflammation the liver, which suffered from asthma and had trouble getting rid of a common cold. Still, Jason has tried to live as normally as possible, though her heart was failing constantly.

His mother called for help after being removed from a heart transplant list. It was then left alone with drugs, I had some unpleasant side effects, and always felt tired and depressed, as he paced back and forth to specialists with their medication reviewed. And then his mother know about therapy with adult stem cells.

Barely a month after gene therapy for adult cells, Jason knows that his life would change, “My heart was beating better, more rhythmic, and I had more energy,” he said. “After six months, I got up and flying, feeling 100 percent different. I could mow the lawn, walking, bicycling with my kids, lift weights – do whatever I wanted, “he said.” I’m always on the road with our fifth child on the road and still working as full-time mother. ”

Jason has always enjoyed a tremendous level of support from family and friends, but is very happy to spend time advising other cardiomyopathy people the power of positive thinking. “We always try to be positive,” he advises. ” There is hope. Watch your diet and get the word adult stem cell therapy is interesting to do. This is nothing like what you might think. ”

Hundreds of people suffering from terminal to terminal failure of the heart, cardiomyopathy or coronary disease, who were impressed by the result of adult stem cells and clinical outcome. Those who said they are without any treatment option now have the option of staying home to await death or to join more than 75 percent which has a life characterized by greater energy and less symptoms.

The adult stem cell therapy, which appears to be a lifeline to all Heart patients who are tired of being sick, or do not want their lives are characterized by restricted activity, low energy, pain, cost and brevity. The trend will continue to grow as people become more aware of that can not be harmed by a therapy that uses their own adult stem cells and that the procedures are simple, effective and performed in world class hospitals by skilled, heart specialists often prominent. Most encouraging clinical outcomes are compatible with the results of research and relationship with patients. If Jason gets the time to train and not a triathlon, the world just sit and take notes.


About the Author:

Jon Bradshaw writes constantly about the next to miraculous effects of adult stem cells. Theravitae’s Vescell adult stem cells the new frontier of regenerative medicine. They offer a return to a more active, longer and healthier life to patients who have heart disease or PAD. They are derived from the patient’s own blood so cannot be rejected by the body.

Article Source: ArticlesBase.comCardiomyopathy Patient Declares He Could Do A Triathlon After Adult Stem Cell Treatment

New Heart, New Love, New Son Courtesy of Adult Stem Cells

In VICTORIES & SUCCESS STORIES on March 8, 2010 at 3:50 pm
Don’t miss any important stem cell news! Follow me on twitter! http://twitter.com/stemcellblogger
New Heart, New Love, New Son Courtesy of Adult Stem Cells

Ten years ago a Surfers Paradise manss life was dominated by heart disease and time was running out. Now he has been granted a new wife and baby son better health total happiness.

Peter Irwin from Surfers Paradise in Queensland, Australia, has much to be thankful for. Ten years ago he was depressed, ill and deeply unhappy. He suffered from both Dilated Cardiomyopathy and some Ischemic Heart Disease that was slowly but surely killing him. Told there was nothing more that could be done for him and with no hope of living beyond another two years he started to seek for someone or something that could give him better odds.

An internet search unearthed that adult stem cells can offer hope and help. Peter failed to get on to a clinical trial in his own country because he was too ill to meet their entry criteria and so he went to Bangkok in October 2005 thinking he had nothing to lose.

Within four months of a simple procedure at a Bangkok Heart Hospital Peter was feeling much better and far more optimistic. His cardiologist had to agree that on clinical tests his heart was performing far more efficiently. His life since then has continued to improve. He still has some health issues but they no longer dominate his life. The greatest improvement has been that he can enjoy a far better quality of life and has high expectations of a very positive future.

Adult stem cell therapy helped his heart strengthen, revascularize and repair and he made other dietary and lifestyle changes that he thinks have also benefited him. If you are beyond hope of treatment because of heart disease, all is not lost, he said. Almost every day research is being published that shows just how many seriously ill heart patients can be returned to a life they thought they had lost.

To cap off all his gains Peter and his new wife have just recently brought into the world a new son. “Stem cells made me reconsider my life. I now have the love and care of a new partner and a son whom I love more than I thought it possible to love. It is indeed a miracle and I am so grateful”, Peter said.

Looking at the family photographs he sent at the time of his son’s birth Peter looks the picture of health and happiness. One would never know that such a short time ago he faced a brief, painful, anxious, hopeless and debilitating future.

Jon Bradshaw writes constantly about the next to miraculous effects of adult stem cells. Theravitae’s Vescell adult stem cells the new frontier of regenerative medicine. They offer a return to a more active, longer and healthier life to patients who have heart disease or PAD. They are derived from the patient’s own blood so cannot be rejected by the body.

Mayo Clinic + stem cell biotech

In STEM CELLS IN THE NEWS on September 2, 2009 at 11:45 am

Kiger’s Notebook – By Jeff Kiger, Post-Bulletin business columnist

September 01, 2009

Mayo Clinic-linked stem cell biotech = “Tremendous potential”

I’ve written about Cardio3, a Belgium biotech that is using Mayo Clinic research as part of its stem cell-based cardiac treatment, a few times before here and here.Today the company kicked out a release about its presentation at the European Society of Cardiology Congress in Barcelona, Spain. Here a little from the release:


A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient’s own cells into ‘cardiopoietic’ cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure…

via Postbulletin.com: Rochester, MN.

Pfizer flushes $100 million down the toilet

In ALL ARTICLES on May 10, 2009 at 12:03 pm

Money stackstoilet

Pfizer is pumping $100 million into its international stem cell development program.
They are going to us embryonic stem cells and see if they have any potential in treating cardiac muscle.
They want to make drugs from the stem cells.

  • $100 million
  • into a science that is at worst, a dead end for creating treatments and at best, will not produce treatments for 20-50 years.
  • to develop drugs (instead of using the stem cells themselves)
  • for a disease that has been treated successfully with adult stem cells since early 2000

So what if embryonic research has been 100% fruitless (in regard to generating treatments) for well-funded and government supported scientists around the world for the last 11 years.

So what if Dr James Thomson, father of embryonic research said about embryonic research: “…embryonic stem cells are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.”

So what if Dr Oz said on national TV “the stem cell debate is dead,” recognizing the lack of potential in embryonic stem cells to produce cures.

So what if Ian Wilmut, who led the team that cloned Dolly the sheep, abandoned his license to attempt human cloning, saying that the researchers “may have achieved what no politician could: an end to the embryonic stem cell debate.”

So what if  Dr. Bernadine Healy, director of the National Institutes of Health under the first President Bush, wrote in U.S. News & World Report that these recent developments “in the first six weeks of Obama’s term, several events reinforced the notion that embryonic stem cells, once thought to hold the cure for Alzheimer’s, Parkinson’s, and diabetes, are obsolete….. In fact, adult stem cells, which occur in small quantities in organs throughout the body for natural growth and repair, have become stars despite great skepticism early on.”

Pfizer forges ahead with dead science.

$100 million…money well spent.

from https://repairstemcell.wordpress.com/2009/03/21/2793/

    original article: http://www.fiercebiotech.com/story/pfizer-pumps-100m-stem-cell-research/2009-05-08

    Adult Stem Cell Research Gives Heart Disease Patient a Miracle | Adult Stem Cell Research

    In ALL ARTICLES, VICTORIES & SUCCESS STORIES on March 16, 2009 at 7:35 pm
    heart victoryAdult Stem Cell Research Gives Heart Disease Patient a Miracle

    Posted 16 March, 2009 in Heart Disease |

    Advances in Stem Cell Research for the Heart

    The doctors had given Aaron Cathcart, a Louisiana native about a year to live. Suffering from congestive heart failure after a major heart attack, Aaron was told he was going to be yet another victim of heart disease. However, thanks to the wonders of Adult Stem Cell research, Aaron is not just living, he is “thriving” after having his own Adult Stem Cells injected back into his heart.

    On June 26th, 2008, Aaron Cathcart was injected with stem cells taken from his own bone marrow and into his heart muscle in Covington, Louisiana in a clinical trial using Adult Stem Cell treatment.

    Before the Adult Stem Cells
    • Ejection Fraction of 20%
    • Couldn’t walk 200 feet without pain
    • Couldn’t go outside if lower than 50 degrees because the cold weather would strain his heart
    After the Stem Cells Were Injected into his Heart Muscle
    • Ejection Fraction of 41%- 6 months later
    • Can now take his dog for nice walks
    • the “non-functioning part of his heart that had received the adult-stem-cell injections was beating again”
    Given His Life Back

    Aaron now feels like he has been given his life back and his new goal is to let others know about this procedure that has saved his life and to “clear up any misconceptions there might be about adult-stem-cell research.

    He also said “Everyone’s body has them (adult stem cells), and if you increase them in concentration, they can repair your body much better than normal,”

    Adult Stem Cells Aren’t Rocket Science

    Once again, Aaron is correct, this isn’t some special rocket science or splitting an atom, it is common sense.  In essence, your own stem cells are already there to repair damage to the body, let the body heal itself.  However, sometimes, there aren’t enough of these stem cells to do that.  Therefore, these doctors/researchers are multiplying the amount of stem cells and then putting them into the area that needs repair- in Aaron’s case it was the heart, and then they let the body’s own repair mechanisms (the adult stem cells)  do what they are “born to do”- no controversy, no ethical concerns, a 3rd grader can understand this-  so why isn’t it available in the United States?

    FDA Regulates Adult Stem Cell Therapy Like a New Drug

    Aaron was one of the lucky ones to qualify for a clinical trial, but while these clinical trials are going on, thousands of lives are being lost because in the United States, adult stem cells aren’t available due to FDA regulations–  regulations that treat a person’s own stem cells just like a new drug from Pfizer or Merkk- meaning 7-10 years until approval.  Until the FDA changes these archaic rules, Americans will suffer needlessly.  I’m at a loss at what to do to change this. Anyone have any ideas?

    More Stem Cell Treatment Information

    Here is the original stem cell article with Aaron Cathcart

    That same article lists contact information for this particular heart disease trial

    Also, for more information on heart disease patients helped by stem cell treatment

    via Adult Stem Cell Research Gives Heart Disease Patient a Miracle | Adult

    %d bloggers like this: